Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190918 · ClinicalTrials.gov registry record · Phase 2
A Trial for Patients With Gestational Trophoblastic Disease
A Phase 2 study of Choriocarcinoma and Uterine Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00190918 is a Phase 2 study of Choriocarcinoma and Uterine Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 50 participants, below the 358-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00190918, a Phase 2 study of Choriocarcinoma and Uterine Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
Conditions Studied
Interventions
- DRUG Pemetrexed
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group 215-854-0770 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190918
The ClinicalTrials.gov registry entry for NCT00190918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Choriocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pemetrexed is the first listed.
NCT00190918 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00190918 about?
NCT00190918 is a clinical study titled "A Trial for Patients With Gestational Trophoblastic Disease". This phase II study is evaluating the activity of Pemetrexed in patients diagnosed with low risk Gestational Trophoblastic Tumor (GTT) that have failed prior treatment.
What is the current status of trial NCT00190918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-07. Estimated completion is 2007-07.
What conditions does trial NCT00190918 study?
This clinical trial studies the following conditions: Choriocarcinoma, Uterine Neoplasms, Hydatidiform Mole, Trophoblastic Neoplasms.
What interventions are being tested in trial NCT00190918?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00190918?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00190918 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choriocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
RECRUITING · Phase 2
-
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
COMPLETED · Phase 2
-
Molecular Epidemiology of Pediatric Germ Cell Tumors
RECRUITING
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.